Nahar Polyfilms manufactures and sells Bi-axially Oriented Polypropylene (BOPP) films, which are primarily used as flexible packaging materials for consumer goods and industrial applications.
The company operates in a highly cyclical and commoditized industry, evidenced by volatile profitability and a low average ROCE of 6.7%. While they possess scale as a top-tier domestic player, they lack durable pricing power, as margins fluctuate significantly based on raw material costs and industry overcapacity.
Management maintains a conservative balance sheet with very low debt, but returns on reinvested capital have been mediocre. They are currently committing significant capital to a third production line despite recent periods of inadequate profitability, suggesting a focus on volume growth over return optimization.
The investment collapsed as the company doubled down on capacity expansion into a global supply glut, turning a conservative balance sheet into a trap of idle assets. While revenue grew, the lack of pricing power meant raw material spikes could not be passed on, causing the already mediocre 6.7% ROCE to crater toward zero. The Nahar Group's complex web of related party transactions and promoter commissions drained the remaining cash flow during the downturn, leaving minority shareholders with a value-trap that prioritized volume and group interests over capital efficiency.
RichFakir rates Nahar Polyfilms Ltd's business quality as mediocre — 42/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Nahar Polyfilms Ltd is trading about 49% below our estimate of fair value; we rate its price cheap. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Nahar Polyfilms Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Nahar Polyfilms Ltd's fair value is about ₹434 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →